Skip to main content
. 2018 Jul 10;2(13):1633–1644. doi: 10.1182/bloodadvances.2017015545

Table 8.

NNH and NNT in ASPIRE and ENDEAVOR trials

ASPIRE ENDEAVOR
Unfavorable effects: NNH (subject year)
 Grade ≥3 cardiac failure* 102.8 30.8
 Grade ≥3 hypertension 75.1 12.9
Favorable effect: NNT (subject year)
 PFS 8.2 2.5
*

Based on standardized MedDRA query, narrow scope.

Based on preferred term.